Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.

McKimm-Breschkin JL, Barrett S, McKenzie-Kludas C, McAuley J, Streltsov VA, Withers SG.

Antiviral Res. 2019 Sep;169:104542. doi: 10.1016/j.antiviral.2019.104542. Epub 2019 Jun 22.

PMID:
31233807
2.

Influenza Virus Neuraminidase Structure and Functions.

McAuley JL, Gilbertson BP, Trifkovic S, Brown LE, McKimm-Breschkin JL.

Front Microbiol. 2019 Jan 29;10:39. doi: 10.3389/fmicb.2019.00039. eCollection 2019. Review.

3.

Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk.

Streltsov VA, Schmidt PM, McKimm-Breschkin JL.

Acta Crystallogr F Struct Biol Commun. 2019 Feb 1;75(Pt 2):89-97. doi: 10.1107/S2053230X18017892. Epub 2019 Jan 23.

PMID:
30713159
4.

Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.

McKimm-Breschkin JL, Barrett S, Wong FYK, Pudjiatmoko, Azhar M, Selleck P, Davies KR, Hartaningsih N, McGrane J.

Antiviral Res. 2018 May;153:95-100. doi: 10.1016/j.antiviral.2018.03.007. Epub 2018 Mar 21.

PMID:
29574145
5.

Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.

McKimm-Breschkin JL, Barrett S, Pilling PA, Hader S, Watts AG, Streltsov VA.

J Med Chem. 2018 Mar 8;61(5):1921-1933. doi: 10.1021/acs.jmedchem.7b01467. Epub 2018 Feb 15.

PMID:
29397718
6.

Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

McKimm-Breschkin JL, Jiang S, Hui DS, Beigel JH, Govorkova EA, Lee N.

Antiviral Res. 2018 Jan;149:118-142. doi: 10.1016/j.antiviral.2017.11.013. Epub 2017 Nov 21.

PMID:
29162476
7.

Mouse Saliva Inhibits Transit of Influenza Virus to the Lower Respiratory Tract by Efficiently Blocking Influenza Virus Neuraminidase Activity.

Gilbertson B, Ng WC, Crawford S, McKimm-Breschkin JL, Brown LE.

J Virol. 2017 Jun 26;91(14). pii: e00145-17. doi: 10.1128/JVI.00145-17. Print 2017 Jul 15.

8.

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.

McKimm-Breschkin JL, Fry AM.

Antiviral Res. 2016 May;129:21-38. doi: 10.1016/j.antiviral.2016.01.012. Epub 2016 Feb 9.

PMID:
26872862
9.

Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).

Streltsov VA, Pilling P, Barrett S, McKimm-Breschkin JL.

Antiviral Res. 2015 Nov;123:216-23. doi: 10.1016/j.antiviral.2015.08.014. Epub 2015 Sep 10.

PMID:
26364554
10.

The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.

Mohr PG, Deng YM, McKimm-Breschkin JL.

Virol J. 2015 Apr 22;12:67. doi: 10.1186/s12985-015-0295-3.

11.

Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.

McKimm-Breschkin JL, Barrett S.

Antiviral Res. 2015 Feb;114:62-6. doi: 10.1016/j.antiviral.2014.12.004. Epub 2014 Dec 9.

PMID:
25499124
12.

Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.

Barrett S, McKimm-Breschkin JL.

Antiviral Res. 2014 Aug;108:30-5. doi: 10.1016/j.antiviral.2014.05.006. Epub 2014 May 20.

13.

Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.

Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS.

mBio. 2013 Jul 16;4(4). pii: e00396-13. doi: 10.1128/mBio.00396-13.

14.

I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.

McKimm-Breschkin JL, Barrett S, Pudjiatmoko, Azhar M, Wong FY, Selleck P, Mohr PG, McGrane J, Kim M.

PLoS One. 2013 Jun 11;8(6):e66105. doi: 10.1371/journal.pone.0066105. Print 2013.

15.

Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

McKimm-Breschkin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, Saito T, Tashiro M.

J Antimicrob Chemother. 2013 Oct;68(10):2210-21. doi: 10.1093/jac/dkt205. Epub 2013 Jun 11.

16.

Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.

Kim JH, Resende R, Wennekes T, Chen HM, Bance N, Buchini S, Watts AG, Pilling P, Streltsov VA, Petric M, Liggins R, Barrett S, McKimm-Breschkin JL, Niikura M, Withers SG.

Science. 2013 Apr 5;340(6128):71-5. doi: 10.1126/science.1232552. Epub 2013 Feb 21.

17.

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.

18.

Taking down the FLAG! How insect cell expression challenges an established tag-system.

Schmidt PM, Sparrow LG, Attwood RM, Xiao X, Adams TE, McKimm-Breschkin JL.

PLoS One. 2012;7(6):e37779. doi: 10.1371/journal.pone.0037779. Epub 2012 Jun 6.

19.

In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.

McKimm-Breschkin JL, Rootes C, Mohr PG, Barrett S, Streltsov VA.

J Antimicrob Chemother. 2012 Aug;67(8):1874-83. doi: 10.1093/jac/dks150. Epub 2012 May 4.

PMID:
22563014
20.

Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.

Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL.

PLoS One. 2011;6(8):e23627. doi: 10.1371/journal.pone.0023627. Epub 2011 Aug 17.

21.

Plaque formation assay for human parainfluenza virus type 1.

Fukushima K, Takahashi T, Takaguchi M, Ueyama H, Ito S, Kurebayashi Y, Kawanishi T, McKimm-Breschkin JL, Takimoto T, Minami A, Suzuki T.

Biol Pharm Bull. 2011;34(7):996-1000.

22.

Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.

Mohr PG, Geyer H, McKimm-Breschkin JL.

Antiviral Res. 2011 Jul;91(1):20-2. doi: 10.1016/j.antiviral.2011.04.010. Epub 2011 Apr 23.

PMID:
21549758
23.

A generic system for the expression and purification of soluble and stable influenza neuraminidase.

Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL.

PLoS One. 2011 Feb 7;6(2):e16284. doi: 10.1371/journal.pone.0016284.

24.

Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL.

J Med Chem. 2010 Sep 9;53(17):6421-31. doi: 10.1021/jm100621s.

25.

Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.

Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, Hayden FG; Neuraminidase Inhibitor Susceptibility Network.

Antivir Ther. 2009;14(6):751-61. doi: 10.3851/IMP1194.

PMID:
19812437
26.

Reduced sensitivity of influenza A (H5N1) to oseltamivir.

McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA.

Emerg Infect Dis. 2007 Sep;13(9):1354-7. doi: 10.3201/eid1309.070164.

27.

Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding.

Smith BJ, Huyton T, Joosten RP, McKimm-Breschkin JL, Zhang JG, Luo CS, Lou MZ, Labrou NE, Garrett TP.

Acta Crystallogr D Biol Crystallogr. 2006 Sep;62(Pt 9):947-52. Epub 2006 Aug 19.

PMID:
16929094
28.

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Z├╝rcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL.

J Antimicrob Chemother. 2006 Oct;58(4):723-32. Epub 2006 Aug 5.

PMID:
16891631
29.

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M.

Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402.

30.

Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.

Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, McKimm-Breschkin JL.

Antimicrob Agents Chemother. 2006 May;50(5):1872-4.

31.
32.
33.
34.

Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.

Hurt AC, McKimm-Breschkin JL, McDonald M, Barr IG, Komadina N, Hampson AW.

Virus Res. 2004 Jul;103(1-2):205-11.

PMID:
15163511
35.

Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III.

Lawrence MC, Borg NA, Streltsov VA, Pilling PA, Epa VC, Varghese JN, McKimm-Breschkin JL, Colman PM.

J Mol Biol. 2004 Jan 30;335(5):1343-57.

PMID:
14729348
36.

Tethered neuraminidase inhibitors that bind an influenza virus: a first step towards a diagnostic method for influenza.

McKimm-Breschkin JL, Colman PM, Jin B, Krippner GY, McDonald M, Reece PA, Tucker SP, Waddington L, Watson KG, Wu WY.

Angew Chem Int Ed Engl. 2003 Jul 14;42(27):3118-21. No abstract available.

PMID:
12866095
37.
38.

Neuraminidase inhibitors for the treatment and prevention of influenza.

McKimm-Breschkin JL.

Expert Opin Pharmacother. 2002 Feb;3(2):103-12. Review.

PMID:
11829724
39.

Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.

Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ.

J Biol Chem. 2001 Oct 19;276(42):38988-94. Epub 2001 Aug 3.

40.

Resistance of influenza viruses to neuraminidase inhibitors--a review.

McKimm-Breschkin JL.

Antiviral Res. 2000 Jul;47(1):1-17. Review. No abstract available.

PMID:
10930642
41.

Virological Methods for the Generation and Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.

McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, Jowett AJ, Bethell RC.

Methods Mol Med. 2000;24:375-82. doi: 10.1385/1-59259-245-7:375.

PMID:
21331924
42.

Biochemical Methods for the Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.

Bethell RC, Hart GJ, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL.

Methods Mol Med. 2000;24:367-74. doi: 10.1385/1-59259-245-7:367.

PMID:
21331923
43.

Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase.

Sahasrabudhe A, Lawrence L, Epa VC, Varghese JN, Colman PM, McKimm-Breschkin JL.

Virology. 1998 Jul 20;247(1):14-21.

44.

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.

Blick TJ, Sahasrabudhe A, McDonald M, Owens IJ, Morley PJ, Fenton RJ, McKimm-Breschkin JL.

Virology. 1998 Jun 20;246(1):95-103.

45.

Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.

Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM.

Structure. 1998 Jun 15;6(6):735-46.

46.

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.

McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC, Varghese JN.

J Virol. 1998 Mar;72(3):2456-62.

47.

Use of oligonucleotide probes for selecting potential high-yielding influenza reassortants.

Sahasrabudhe A, Ekkel S, Hampson AW, McKimm-Breschkin JL.

J Virol Methods. 1997 Nov;68(2):139-45.

PMID:
9389403
48.

Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.

Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12.

50.

Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, Bethell RC, Penn CR.

Antimicrob Agents Chemother. 1996 Jan;40(1):40-6.

Supplemental Content

Loading ...
Support Center